using System;
using System.Collections.Generic;
using System.Linq;
using System.Text;

namespace YellowstonePathology.Business.Test.HER2AmplificationByISH
{
	public class HER2AmplificationByISHResult : YellowstonePathology.Business.Test.TestResult
	{
		protected string m_InterpretiveCommentP4IHCOrder = "HER2 immunohistochemistry will be performed and results will be issued in an addendum to the original surgical pathology report.";
		protected string m_InterpretiveComment;
		protected string m_ResultComment;
		protected string m_ResultDescription;
		protected string m_ReportReference;
		protected string PositiveResult = "POSITIVE (amplified)";
		protected string NegativeResult = "NEGATIVE (not amplified)";
		protected string EquivocalResult = "EQUIVOCAL";
		protected string IndeterminateResult = "INDETERMINATE";
		protected string PositiveResultCode = "HRMPLFCTNBISHPSTV";
		protected string NegativeResultCode = "HRMPLFCTNBISHNGTV";
		protected string EquivocalResultCode = "HRMPLFCTNBISHQVCL";
		protected string IndeterminateResultCode = "HRMPLFCTNBISHNDTRMNT";
		protected string m_Method = "This test was performed using a molecular method, In Situ Hybridization (ISH) with the US FDA approved Inform HER2 DNA probe kit, modified to report results according to ASCO/CAP guidelines. The test was performed on paraffin embedded tissue in compliance with ASCO/CAP guidelines.  Probes used include a locus specific probe for HER2 and an internal hybridization control probe for the centromeric region of chromosome 17 (Chr17).";
		protected string m_ASRComment = "This test was performed using a US FDA approved DNA probe kit, modified to report results according to ASCO/CAP guidelines, and the modified procedure was validated by Yellowstone Pathology Institute (YPI).  YPI assumes the responsibility for test performance";
        protected string m_FixationOutOfBoundsComment = "The specimen fixation time does not meet ASCO CAP guidelines (6 to 72 hours), which may cause false negative results.  Repeat testing on an alternate specimen that meets fixation time guidelines is recommended, if available.";
        protected string m_FixationColdSchemaComment = "The time from specimen procurement to fixation in formalin (cold ischemia time) exceeds one hour, which may cause false negative results.  Repeat testing on an alternate specimen that meets ASCO CAP guidelines for cold ischemia time is recommended, if available.";

        public HER2AmplificationByISHResult()
		{
			this.m_ResultComment = null;
			this.m_InterpretiveComment = null;
			this.m_ResultDescription = null;
			this.m_ReportReference = null;
		}

		public virtual void SetResults(HER2AmplificationByISHTestOrder testOrder, Business.Specimen.Model.SpecimenOrder specimenOrder)
		{
			if (testOrder.GeneticHeterogeneity == HER2AmplificationByISHGeneticHeterogeneityCollection.GeneticHeterogeneityPresentInCells)
			{
				this.m_InterpretiveComment += Environment.NewLine + Environment.NewLine +
					"However, this tumor exhibits genetic heterogeneity in HER2 gene amplification in scattered individual cells.  The " +
					"clinical significance and potential clinical benefit of trastuzumab is uncertain when " +
					testOrder.Indicator.ToLower() +
					"carcinoma demonstrates genetic heterogeneity." + Environment.NewLine + Environment.NewLine;
				this.m_ResultComment = "This tumor exhibits genetic heterogeneity in HER2 gene amplification in scattered individual cells.  The clinical " +
					"significance and potential clinical benefit of trastuzumab is uncertain when " +
					testOrder.Indicator.ToLower() + 
					" carcinoma demonstrates genetic heterogeneity";
			}
			else if (testOrder.GeneticHeterogeneity == HER2AmplificationByISHGeneticHeterogeneityCollection.GeneticHeterogeneityPresentInClusters)
			{
				this.m_InterpretiveComment += Environment.NewLine + Environment.NewLine + 
					"However, this tumor exhibits genetic heterogeneity in HER2 gene amplification in small cell clusters. The HER2/Chr17 " +
					"ratio in the clusters is " +
					testOrder.Her2Chr17ClusterRatio +
					".  The clinical significance and potential clinical benefit of trastuzumab is uncertain when " +
					testOrder.Indicator.ToLower() + 
					" carcinoma demonstrates genetic heterogeneity." + Environment.NewLine + Environment.NewLine;
				this.m_ResultComment = "This tumor exhibits genetic heterogeneity in HER2 gene amplification in small cell clusters.  The clinical significance " +
					"and potential clinical benefit of trastuzumab is uncertain when " +
					testOrder.Indicator.ToLower() + 
					" carcinoma demonstrates genetic heterogeneity.";
			}

			testOrder.Result = this.m_Result;
			testOrder.ResultCode = this.m_ResultCode;
			testOrder.ResultComment = this.m_ResultComment;
			testOrder.InterpretiveComment = this.m_InterpretiveComment.TrimEnd();
			testOrder.ResultDescription = this.m_ResultDescription;
			testOrder.CommentLabel = null;
			testOrder.Method = this.m_Method;
			testOrder.ReportReference = this.m_ReportReference;
			testOrder.ASRComment = this.m_ASRComment;
            testOrder.NoCharge = false;

            if(specimenOrder.FixationDuration > 72 || specimenOrder.FixationDuration < 6)
            {
                specimenOrder.FixationComment = m_FixationOutOfBoundsComment;
            }
		}

		public static void AcceptResults(HER2AmplificationByISHTestOrder testOrder, YellowstonePathology.Business.User.SystemIdentity systemIdentity)
		{
			testOrder.Accept();
			if (testOrder.PanelOrderCollection.GetUnacceptedPanelCount() > 0)
			{
				YellowstonePathology.Business.Test.PanelOrder panelOrder = testOrder.PanelOrderCollection.GetUnacceptedPanelOrder();
				panelOrder.AcceptResults();
			}
		}

		public static void UnacceptResults(HER2AmplificationByISHTestOrder testOrder)
		{
			testOrder.Unaccept();
			if (testOrder.PanelOrderCollection.GetAcceptedPanelCount() > 0)
			{
				YellowstonePathology.Business.Test.PanelOrder panelOrder = testOrder.PanelOrderCollection.GetLastAcceptedPanelOrder();
				panelOrder.UnacceptResults();
			}
		}
	}
}
